MOLNUPIRAVIR
Background and Date of Approval
Molnupiravir is an antiviral medication containing the active ingredient Molnupiravir. It is indicated for the treatment of mild to moderate COVID-19 (Coronavirus disease) in patients at risk of developing severe illness. COVID-19 is a highly contagious disease caused by the SARS-CoV-2 virus. Molnupiravir is not recommended for adolescents and children younger than 18 years of age. The medication should be initiated within five days of symptom onset for optimal effectiveness. Molnupiravir may offer an alternative treatment option for patients with COVID-19 who cannot tolerate or do not respond adequately to existing therapeutic options, including monoclonal antibodies or remdesivir.
Uses
Molnupiravir is an antiviral drug used to treat mild to moderate COVID-19 in high-risk adults.
How is it administered?
Take Molnupiravir in the dose and duration prescribed by your doctor. Swallow the medication whole with plenty of water. Do not chew or crush the capsules. This capsule can be taken with or without food. Do not skip or miss doses.
Side Effects
Molnupiravir may cause side effects, some of which may be serious. The most common side effects reported in clinical trials were diarrhea, nausea, and vomiting. Other common side effects include headache, fatigue, and abdominal pain. Serious side effects that have been reported include anaphylaxis (severe allergic reaction), increased risk of bleeding, and liver injury.
Warnings
Some patients may experience allergic reactions to Molnupiravir, which can be serious or life-threatening in some cases. The safety and effectiveness of patients with severe renal impairment or end-stage renal disease have not been established. The safety and effectiveness of this medication in immunocompromised patients have not been established.
Precautions
Patients require monitoring for signs of an allergic reaction, such as rash, hives, or difficulty breathing, and should seek medical attention immediately if any such symptoms occur. Patients with impaired renal function need careful attention to potential adverse effects and may require dosage adjustments.
Word of Advice
If Molnupiravir has been prescribed to you, careful review of the associated warnings and precautions is essential. The medication increases infection risk, so patients should minimise close contact with infected individuals. Pregnant women and those who are breastfeeding must consult a healthcare provider before use. Effective birth control measures should be employed during treatment and for at least four days after the final dose. Do not discontinue Molnupiravir without physician consultation, as stopping treatment elevates the risk of severe COVID-19. Patients must avoid contact with infected individuals. Maintenance of a healthy, balanced diet supports overall health and well-being.
References
Merck Sharp & Dohme (UK) Limited, Electronic medicines compendium (emc), [ Revised on Nov 2021] [ Accessed on 9th May 2023], https://www.medicines.org.uk/emc/files/pil.13044.pdf Florian Kabinger et al; Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis; Nature Structural & Molecular Biology; [Published on 11/08/2021]; [Accessed on 9 May 2023]; https://www.nature.com/articles/s41594-021-00651-0 William Fischer et al; Molnupiravir, an Oral Antiviral Treatment for COVID-19; medRxiv; [Published on 17/06/2021]; [Accessed on 9th May 2023], https://pubmed.ncbi.nlm.nih.gov/34159342/
Frequently Asked Questions
Can Molnupiravir be used to prevent COVID-19?
Molnupiravir is currently being studied as a post-exposure prophylaxis (PEP) to prevent COVID-19 infection in people exposed to the virus. However, it is not currently approved for this use.
Can Molnupiravir be used to treat other viral infections?
Molnupiravir is a broad-spectrum antiviral medication effective against a wide range of RNA viruses in laboratory studies. It is currently being studied for other viral infections, such as influenza, but it is not approved for any indication other than COVID-19.
Can Molnupiravir be taken with food?
Yes, Molnupiravir can be taken with or without food. However, taking the medication with food may help reduce the risk of gastrointestinal side effects.
Can Molnupiravir be used in pediatric patients?
Molnupiravir has not been studied in pediatric patients under 18, and the drug is not currently approved for use in this population. Studies are ongoing to evaluate the safety and efficacy of Molnupiravir in pediatric patients.
Can Molnupiravir be used to treat severe COVID-19?
Molnupiravir is currently being studied for use in mild to moderate COVID-19 cases and is not recommended in severe cases of the disease. It is important to consult with a healthcare provider to determine the appropriate treatment for COVID-19 based on the patient's health status and symptoms.
Can Molnupiravir be used as a substitute for COVID-19 vaccines?
No, Molnupiravir is not a substitute for COVID-19 vaccines. Vaccines are the most effective way to prevent COVID-19 infection and its complications, while Molnupiravir is a treatment for people who have already been infected.
Can I use Molnupiravir for impaired kidney patients?
The safety and efficacy of Molnupiravir in patients with impaired kidney function have yet to be specifically studied. However, according to the prescribing information, Molnupiravir is primarily eliminated through the liver and does not undergo significant renal excretion. Therefore, no dose adjustment is recommended for patients with mild to moderate kidney impairment.